Eighteen percent of patients on KYNAMRO and 2% of patients on placebo discontinued treatment due to adverse reactions.

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

Compared with placebo, treatment with Belviq for up to one year was associated with average weight loss ranging from 3 percent to 3.7 percent.

FORBES: Arena Obesity Drug Approval Looks Like Best-Case Scenario

Pain is another nerve-related symptom susceptible to treatment by placebo.

ECONOMIST: Alternative medicine: Think yourself better | The

This study randomly divided patients into two groups - one received the antibiotic and the other was given a placebo, an inert treatment in the form of a sugar pill, three times a day for seven days.

BBC: Antibiotics 'ineffective for coughs'

Safety data for KYNAMRO are based on pooled results from four Phase 3, randomized, double-blind, placebo-controlled trials with a total of 390 patients of which 261 patients received weekly subcutaneous injections of 200 mg of KYNAMRO and 129 patients received placebo for a median treatment duration of 25 weeks.

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

However, these glowing results have a glaring weakness: They don't compare Velcade against a standard treatment or a placebo.

FORBES: Magazine Article

Or maybe a treatment will have "a placebo effect, " meaning it will make you feel better just because you have confidence it will make you feel better.

CNN: Is your doctor prescribing a placebo?

Rather, it found that although both forms of treatment were better than a placebo, there was no statistical difference between the results from the use of talk therapy and the popping of Lexapro.

ECONOMIST: Medical journals and ethics

The researchers found individuals with a COMT variant that triples the amount of dopamine in the front of the brain felt no improvement without treatment but an improvement with the placebo acupuncture.

BBC: Placebo effect may be 'down to genes'

VX-661 was generally well-tolerated, both as monotherapy and in combination with ivacaftor, and most adverse events were mild to moderate in severity and similar between the treatment groups and those who received placebo.

FORBES: Personalized Cystic Fibrosis Drugs Get A Booster Shot

Patients who received TSO treatment improved significantly more than those who got placebo.

WSJ: In a Squeaky-Clean World, a Worm Might Help Fight Disease

The most common adverse reactions in patients treated with KYNAMRO that led to treatment discontinuation and occurred at a rate greater than placebo were: injection site reactions (5.0%), alanine aminotransferase (ALT) increased (3.4%), flu-like symptoms (2.7%), aspartate aminotransferase (AST) increased (2.3%), and liver function test abnormal (1.5%).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

These new events were distributed equally between the three treatment groups (2.5 mg, 5 mg and placebo) of patients who were alive (806) and those who had died (37).

FORBES: FDA Again Rejects ACS Indication for Rivaroxaban (Xarelto)

The data monitoring committee overseeing the trial said patients were unlikely to benefit from the treatment, and identified higher adverse events in the subjects receiving the drug compares to placebo.

FORBES: European Pharma Stocks Hit on Bad News

Patients who did not get Provenge did not receive a true placebo, but instead a sham version of Provenge followed by a frozen Provenge they could receive the treatment later on. (Provenge involves removing, altering, and replacing immune cells.) Patients who did get Provenge may have gotten placebo faster.

FORBES: Dendreon Data Are Merely Moderate, But Stock Surges Anyway